SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending sharply higher after President Trump announced a "framework" deal with NATO regarding Greenland and unexpectedly reversed course on potential new tariffs against Europe. This geopolitical de-escalation is sparking a significant market rally, with many traders labeling it a "TACO" (Trump Always Chickens Out) trade as market fears rapidly dissipate. Community discussion highlights the immediate bullish reaction, while some question the broader implications of such swift policy reversals on market stability.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is seeing significant activity as President Trump's announcement of a Greenland "framework" and the suspension of EU tariffs fueled a rapid market rebound. Traders are actively discussing the "TACO trade," where initial geopolitical uncertainty quickly reversed, leaving bears burned and reinforcing the "buy the dip" strategy amidst perceived market manipulation. This volatility underscores how headline-driven events continue to create dramatic swings in market sentiment.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending after announcing a new licensing agreement with Pfizer for its Matrix-M adjuvant technology, which the community sees as a major validation for its platform. Investors are keenly discussing the potential for a substantial short squeeze, fueled by high short interest and expectations of more partnerships for Matrix-M as a multi-billion dollar asset.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending amid high community discussion regarding its Anktiva immunotherapy, with optimism fueled by anticipated FDA advancements for bladder cancer and recent international regulatory wins. Investors are actively debating a potential short squeeze, given the substantial short interest and rising borrow costs, while also highlighting the company's ambitious goal to revolutionize cancer treatment. The broader context of global approvals and a strong product pipeline sustains a bullish outlook despite market volatility.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

The Metals Company (TMC) is generating significant buzz as investors keenly follow recent U.S. regulatory updates, including streamlined deep-sea mining permit processes and an upcoming Congressional hearing featuring TMC's CEO. The community anticipates a major breakout, driven by increasing recognition of deep-sea minerals as a national security priority and the potential for expedited commercial recovery.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is actively discussed amidst evolving geopolitical developments surrounding Greenland's rare earth mineral rights, particularly following recent statements from former President Trump and upcoming business updates. Investors are closely watching for definitive outcomes, with many anticipating a significant boost from any potential deal securing U.S. access to Greenland's vast critical metal deposits, despite notable short-term volatility and accusations of market manipulation.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing significant volatility following Donald Trump's comments from Davos, which included remarks on tariffs and crypto legislation. The community remains fiercely divided, with some anticipating a major short squeeze and new all-time highs, while others warn of institutional manipulation and potential bear traps amid the turbulent price action.

PAVmed, Inc. is a multi-product life sciences company, which engages in the innovation, development, acquisition, and commercialization of products that target unmet medical needs with large addressable market opportunities. Its products include Lucid Diagnostics and Veris Health. The company was founded by Lishan Aklog and Brian J. deGuzman on June 26, 2014 and is headquartered in New York, NY.

PAVmed Inc

PAVmed is currently trending after its subsidiary, Lucid Diagnostics, secured a significant contract with the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test. This news has ignited intense community discussion, with traders anticipating a potential short squeeze and substantial upside given the stock's low float and the expanded market access within the VA healthcare system. Many are celebrating significant gains and drawing comparisons to other recently volatile low-float plays.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital (NUAI) is trending due to a significant partnership with Primary Digital Infrastructure for a massive AI data center campus in West Texas, coupled with a key acquisition. The community is actively discussing strong price action and anticipating an imminent announcement regarding a hyperscaler tenant, fueling speculation of continued upward momentum and a potential short squeeze within the burgeoning AI infrastructure sector.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk (SNDK) is fueling intense market debate following an extraordinary, near-parabolic rally driven by surging demand for memory and data storage, particularly from the AI infrastructure sector, amidst tight supply. While many celebrate its astronomical gains and anticipate further upside, a vocal group warns of an unsustainable bubble nearing a dramatic correction. The divergence of opinion creates a highly charged environment as traders watch for signs of exhaustion or continued momentum.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Insider Selling: Terns Pharmaceuticals (NASDAQ:TERN) CEO Sells 68,749 Shares of Stock

Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) CEO Amy Burroughs sold 68,749 shares of the firm's stock in a transaction on Thursday, January 15th. The shares were sold at an average...

Terns Pharmaceuticals (NASDAQ:TERN) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of Terns Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday...

Insider Selling: Terns Pharmaceuticals (NASDAQ:TERN) CEO Sells $2,548,525.43 in Stock

Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) CEO Amy Burroughs sold 68,749 shares of Terns Pharmaceuticals stock in a transaction that occurred on Thursday, January 15th. The shares...

<ul class="summary-bullets"><li>Viking CEO Brian Lian said at the conference earlier this week that the strategic interest in weight-loss drug deals is broader than it appears.</li><li>Lian also said in October that the company is “certainly receptive” to outside interest in its obesity program.</li><li>Novo recently lost out to Pfizer in the bidding war for smaller obesity drugmaker Metsera but completed its acquisition of Akero therapeutics in December.</li></ul>Shares of obesity drugmaker Viking Therapeutics (VKTX) rallied 17% on Wednesday after Denmark-based Wegovy producer Novo Nordisk (NVO) said it is on the lookout for merger and acquisition deals to boost its drug portfolio.Novo CEO Mike Doustdar said on Tuesday during the annual JP Morgan Healthcare conference that the company will continue searching for molecules, assets, and companies that are complementary to its portfolio.Other obesity drug manufacturing stocks also rallied at the time of writing, including Terns Pharmaceuticals (TERN), and Structure Therapeutics (GPCR). <a href="https://stocktwits.com/symbol/TERN">TERN shares</a> rose 10% at the time of writing while <a href="https://stocktwits.com/symbol/GPCR">GPCR stock</a> rose 6%.<h2 class="st-heading-2">Novo’s Recent Acquisition Attempts</h2>Doustdar said that the company can afford any amount for an asset, provided it is worth it. Talking about Novo Nordisk’s recent $10 billion bid to acquire smaller obesity drug maker Metsera, the CEO said, “We stopped at $10 billion in Metsera because to us, it was not worth a penny more.” Novo <a href="https://stocktwits.com/news-articles/markets/equity/pfizer-ceo-eyes-big-push-towards-obesity-drug-development-in-2026/cmUafq6R4ED">lost out to Pfizer</a> in the bidding war.However, in December, Novo completed its acquisition of Akero Therapeutics for up to $5.2 billion in a bid to gain access to its experimental drug Efruxifermin, being developed for the treatment of compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH).<h2 class="st-heading-2">Viking’s Obesity Pipeline</h2>The subcutaneous formulation of Viking Therapeutics' lead candidate VK2735 is currently in late-stage trials for obesity. In a mid-stage trial, patients achieved up to 14.7% mean weight loss in 13 weeks on the drug.The company is also studying a tablet formulation of the drug.Viking CEO Brian Lian said at the conference earlier this week that the strategic interest in weight-loss drug deals is broader than it appears."I think the interest is probably broader than is visible. I think that there are more parties sort of circling around the space and very intrigued," Lian said while adding that he thinks there is a "fair amount of interest” across the industry.Lian also said in October that the company is “certainly receptive” to outside interest in its obesity program.“...having a larger party involved would be, you know, very helpful in driving the program through commercialization,” he said. “That said, I don't think it's mandatory. I think it's probably a preference, but it's not mandatory. We're prepared to go alone, but we're also prepared to engage with anybody who's interested.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around VKTX stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user opined that Novo might buy Viking for about $10 billion, representing massive upside from its current near $4 billion market cap.<stembedurl>https://www.stocktwits.com/CPA_/message/641819411</stembedurl><a href="https://stocktwits.com/symbol/VKTX">VKTX stock</a> has gained 5% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-bear-says-new-fsd-subscription-model-proves-the-tech-is-not-an-asset/cmULNffR4eU">Tesla Bear Says New FSD Subscription Model Proves The Tech Is Not An Asset: Retail Echoes Concerns</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Viking Therapeutics, Inc., in front of a screen showing the company's latest stock market chart on July 19, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

VKTX, TERN, GPCR Shares Rally As Novo Nordisk Sounds Willingness Towards Portfolio-Expansion Deals

Novo CEO Mike Doustdar said on Tuesday during the annual JP Morgan Healthcare conference that the company will continue searching for molecules, assets and companies that are complementary to its portfolio. 

Equity

Novo CEO Mike Doustdar said on Tuesday during the annual JP Morgan Healthcare conference that the company will continue searching for molecules, assets and companies that are complementary to its portfolio. 


Terns Pharmaceuticals (NASDAQ:TERN) Trading Up 10.4% - Should You Buy?

Terns Pharmaceuticals (NASDAQ:TERN) Stock Price Up 10.4% - Still a Buy...

Terns Pharmaceuticals (NASDAQ:TERN) Trading Down 6.3% - Here's Why

Terns Pharmaceuticals (NASDAQ:TERN) Trading Down 6.3% - Here's Why...

Terns Pharmaceuticals (NASDAQ:TERN) CEO Amy Burroughs Sells 71,339 Shares

Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) CEO Amy Burroughs sold 71,339 shares of the firm's stock in a transaction on Monday, January 5th. The stock was sold at an average price of...

Insider Selling: Terns Pharmaceuticals (NASDAQ:TERN) Insider Sells 1,155 Shares of Stock

Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) insider Emil Kuriakose sold 1,155 shares of the business's stock in a transaction dated Friday, January 2nd. The stock was sold at an...

Terns Pharmaceuticals (NASDAQ:TERN) CEO Sells $2,718,015.90 in Stock

Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) CEO Amy Burroughs sold 71,339 shares of the stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average...

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Average Recommendation of "Moderate Buy" from Brokerages

Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the thirteen analysts that are presently covering the stock, Marketbeat.com...

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Terns Pharmaceuticals Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Current Price	$37.05
Prev Close	$36.58
Open	$36.45
Dividend Yield	0.00%
50-Day Moving Average	$33.75
Beta	1.06
Avg. Volume	4.53M
PE Ratio	-35.45

52-Week High	$48.26
52-Week Low	$1.87
Market Capitalization	$3.89B
EPS (Annual)	-$1.12
Price to Book	11.27
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

TERN
Terns Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TERN News

TERNTerns Pharmaceuticals Inc